News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

96-week PULSAR data support aflibercept 8 mg for nAMD
29 May 2026
byAudrey Abella
Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).








